Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 227-236

  Wang, Feng ^a   Hui, He ^a   Barnes, Timothy J ^a   Barnett, Christian ^b   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b pSiMedica Ltd   (United Kingdom)

Author keywords

In vitro dissolution; In vitro in vivo correlation (IVVC); In vivo pharmacokinetics; Poorly soluble drugs; Porous silicon; Solid state stability

Indexed keywords

DRUG CARRIER; GENERIC DRUG; INDOMETACIN; MESOPOROUS SILICON MICROPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; RAT; SOLID STATE; STORAGE; STRUCTURE ANALYSIS; SURFACE PROPERTY; THERMOGRAVIMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; INDOMETHACIN; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POWDER DIFFRACTION; RATS; RATS, SPRAGUE-DAWLEY; SILICON; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; WATER;

EID: 76249133449     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900221e     Document Type: Article

References (70)

1. Takagi, T.; Ramachandran, C.; Bermejo, M.; Yamashita, S.; Yu, L. X.; Amidon, G. L. A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan. Mol. Pharmaceutics 2006, 3 (6), 631-643.
2. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm. Res. 1995, 12 (3), 413-420.
3. Casella, R.; Williams, D. A.; Jambhekar, S. S. Solid-state [beta]-cyclodextrin complexes containing indomethacin, ammonia and water. II. Solubility studies. Int. J. Pharm. 1998, 165 (1), 15-22.
4. DiNunzio, J. C.; Miller, D. A.; Yang, W.; McGinity, J. W.; Williams, R. O., III. Amorphous Compositions Using Concentration Enhancing Polymers for Improved Bioavailability of Itraconazole. Mol. Pharmaceutics 2008, 5 (6), 968-980.
5. Fini, A.; Cavallari, C.; Ospitali, F. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles. Eur. J. Pharm. Biopharm. 2008, 70, 409-420.
6. Kennedy, M.; Hu, J.; Gao, P.; Li, L.; Ali-Reynolds, A.; Chal, B.; Gupta, V.; Ma, C.; Mahajan, N.; Akrami, A.; Surapaneni, S. Enhanced Bioavailability of a Poorly Soluble VR1 Antagonist Using an Amorphous Solid Dispersion Approach: A Case Study. Mol. Pharmaceutics 2008, 5 (6), 981-993.
7. Tran, P. H. L.; Tran, H. T. T.; Lee, B.-J. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J. Controlled Release 2008, 129 (1), 59-65.
8. Lakshman, J. P.; Cao, Y.; Kowalski, J.; Serajuddin, A. T. M. Application of Melt Extrusion in the Development of a Physically and Chemically Stable High-Energy Amorphous Solid Dispersion of a Poorly Water-Soluble Drug. Mol. Pharmaceutics 2008, 5 (6), 994-1002.
9. Matteucci, M. E.; Brettmann, B. K.; Rogers, T. L.; Elder, E. J.; Williams, R. O., III; Johnston, K. P. Design of Potent Amorphous Drug Nanoparticles for Rapid Generation of Highly Supersaturated Media. Mol. Pharmaceutics 2007, 4 (5), 782-793.
10. Tan, A.; Simovic, S.; Davey, A. K.; Rades, T.; Prestidge, C. A. Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. J. Controlled Release 2009, 134 (1), 62-70.
11. Simovic, S.; Heard, P.; Hui, H.; Song, Y.; Peddie, F.; Davey, A. K.; Lewis, A.; Rades, T.; Prestidge, C. A. Dry Hybrid Lipid-Silica Microcapsules Engineered from Submicron Lipid Droplets and Nanoparticles as a Novel Delivery System for Poorly Soluble Drugs. Mol. Pharmaceutics 2009, 6 (3), 861-872.
12. Crowley, K. J.; Zografi, G. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J. Pharm. Sci. 2002, 91 (2), 492-507.
13. Schmidt, A. G.; Wartewig, S.; Picker, K. M. Potential of carrageenans to protect drugs from polymorphic transformation. Eur. J. Pharm. Biopharm. 2003, 56 (1), 101-110.
14. Strachan, C. J.; Rades, T.; Newnham, D. A.; Gordon, K. C.; Pepper, M.; Taday, P. F. Using terahertz pulsed spectroscopy to study crystallinity of pharmaceutical materials. Chem. Phys. Lett. 2004, 390 (1-3), 20-24.
15. Karjalainen, M.; Airaksinen, S.; Rantanen, J.; Aaltonen, J.; Yliruusi, J. Characterization of polymorphic solid-state changes using variable temperature X-ray powder diffraction. J. Pharm. Biomed. 2005, 39 (1-2), 27-32.
16. Masuda, K.; Tabata, S.; Kono, H.; Sakata, Y.; Hayase, T.; Yonemochi, E.; Terada, K. Solid-state 13C NMR study of indomethacin polymorphism. Int. J. Pharm. 2006, 318 (1-2), 146-153.
17. Muster, T. H.; Prestidge, C. Face specific surface properties of pharmaceutical crystals. J. Pharm. Sci. 2002, 91 (6), 1432-1444.
18. Newman, A.; Engers, D.; Bates, S.; Ivanisevic, I.; Kelly, R. C.; Zografi, G. Characterization of amorphous API:Polymer mixtures using X-ray powder diffraction. J. Pharm. Sci. 2008, 97 (11), 4840-4856.
19. Pan, X.; Julian, T.; Augsburger, L. Increasing the Dissolution Rate of a Low-Solubility Drug Through a Crystalline-Amorphous Transition: A Case Study with Indomethicin. Drug Dev. Ind. Pharm. 2008, 34 (2), 221-231.
20. Zhu, L.; Wong, L.; Yu, L. Surface-Enhanced Crystallization of Amorphous Nifedipine. Mol. Pharmaceutics 2008, 5 (6), 921-926.
21. Zahedi, P.; Lee, P. I. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels. Eur. J. Pharm. Biopharm. 2007, 65 (3), 320-328.
22. Watanabe, T.; Hasegawa, S.; Wakiyama, N.; Kusai, A.; Senna, M. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int. J. Pharm. 2003, 250 (1), 283-286.
23. Chauhan, B.; Shimpi, S.; Paradkar, A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur. J. Pharm. Sci. 2005, 26 (2), 219-230.
24. Takeuchi, H.; Nagira, S.; Tanimura, S.; Yamamoto, H.; Kawashima, Y. Tabletting of Solid Dispersion Particles Consisting of Indomethacin and Porous Silica Particles. Chem. Pharm. Bull. 2005, 53 (5), 487-491.
25. Aguzzi, C.; Cerezo, P.; Viseras, C.; Caramella, C. Use of clays as drug delivery systems: Possibilities and limitations. Appl. Clay Sci. 2007, 36 (1-3), 22-36.
26. Canham, L. T. Silicon quantum wire array fabrication by electrochemical and chemical dissolution of wafers. Appl. Phys. Lett. 1990, 57 (10), 1046-1048.
27. Goh, A. S.-W.; Chung, A. Y.-F.; Lo, R. H.-G.; Lau, T.-N.; Yu, S. W.-K.; Cheng, M.; Satchithanantham, S.; Loong, S. L.-E.; Ng, D. C.-E.; Lim, B.-C.; Connor, S.; Chow, P. K.-H. A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device - a first-in-man study. Int. J. Radiat. Oncol. 2007, 67 (3), 786-792.
28. Pacholski, C.; Sartor, M.; Sailor, M. J.; Cunin, F.; Miskelly, G. M. Biosensing using porous silicon double-layer interferometers: Reflective interferometric Fourier transform spectroscopy. J. Am. Chem. Soc. 2005, 127 (33), 11636-11645.
29. Palestino, G.; Agarwal, V.; Aulombard, R.; Pérez, E.; Gergely, C. Biosensing and Protein Fluorescence Enhancement by Functionalized Porous Silicon Devices. Langmuir 2008, 24 (23), 13765-13771.
30. Prestidge, C. A.; Barnes, T. J.; Mierczynska-Vasilev, A.; Kempson, I.; Peddie, F.; Lau, C. H. Peptide and protein loading into porous silicon wafers. Phys. Status Solidi A 2008, 205 (2), 311-315.
31. Prestidge, C. A.; Barnes, T. J.; Mierczynska-Vasilev, A.; Skinner, W.; Peddie, F.; Barnett, C. Loading and release of a model protein from porous silicon powders. Phys. Status Solidi A 2007, 204 (10), 3361-3366.
32. Salonen, J.; Laitinen, L.; Kaukonen, A. M.; Tuura, J.; Bjorkqvist, M.; Heikkila, T.; Vaha-Heikkila, K.; Hirvonen, J.; Lehto, V. P. Mesoporous silicon microparticles for oral drug delivery: Loading and release of five model drugs. J. Controlled Release 2005, 108 (2-3), 362-374.
33. Salonen, J.; Kaukonen, A. M.; Hirvonen, J.; Lehto, V.-P. Mesoporous silicon in drug delivery applications. J. Pharm. Sci. 2007, 97 (2), 632-653.
34. Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous silicon in drug delivery devices and materials. Adv. Drug Delivery Rev. 2008, 60 (11), 1266-1277.
35. Prestidge, C. A.; Barnes, T. J.; Lau, C.-H.; Barnett, C.; Loni, A.; Canham, L. Mesoporous silicon: A platform for delivery of therapeutics. Expert Opin. Drug Delivery 2007, 4 (2), 101-110.
36. Jarvis, K. L.; Barnes, T. J.; Badalyan, A.; Pendleton, P.; Prestidge, C. A. Impact of Thermal Oxidation on the Adsorptive Properties and Structure of Porous Silicon Particles. J. Phys. Chem. C 2008, 112 (26), 9717-9722.
37. Jarvis, K. L.; Barnes, T. J.; Prestidge, C. A. Aqueous and Thermal Oxidation of Porous Silicon Microparticles: Implications on Molecular Interactions. Langmuir 2008, 24 (24), 1422-14226.
38. Arroyo-Hernandez, M.; Martin-Palma, R. J.; Torres-Costa, V.; Duart, J. M. M. Porous silicon optical filters for biosensing applications. J. Non-Cryst. Solids 2006, 352 (23-25), 2457-2460.
39. Furbert, P.; Lu, C.; Winograd, N.; DeLouise, L. Label-Free Optical Detection of Peptide Synthesis on a Porous Silicon Scaffold/Sensor. Langmuir 2008, 24 (6), 2908-2915.
40. Ciampi, S.; Böcking, T.; Kilian, K. A.; James, M.; Harper, J. B.; Gooding, J. J. Functionalization of Acetylene-Terminated Monolayers on Si(100) Surfaces: A Click Chemistry Approach. Langmuir 2007, 23, 9320-9329.
41. Britcher, L.; Barnes, T. J.; Griesser, H. J.; Prestidge, C. A. PEGylation of Porous Silicon Using Click Chemistry. Langmuir 2008, 24 (15), 7625-7627.
42. Ciampi, S.; Böcking, T.; Kilian, K. A.; Harper, J. B.; Gooding, J. J. Click Chemistry in Mesoporous Materials: Functionalization of Porous Silicon Rugate Filters. Langmuir 2008, 24 (11), 5888-5892.
43. Marion, W. F. V. Indomethacin in the treatment of soft tissue lesions: a double-blind study against placebo. J. Int. Med. Res. 1973, 1, 151-158.
44. Andronis, V.; Zografi, G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J. Non-Cryst. Solids 2000, 271 (3), 236-248.
45. Takeuchi, H.; Nagira, S.; Yamamoto, H.; Kawashima, Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int. J. Pharm. 2005, 293 (1-2), 155-164.
46. Watanabe, T.; Wakiyama, N.; Usui, F.; Ikeda, M.; Isobe, T.; Senna, M. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 2001, 226 (1-2), 81-91.
47. USP30, The United States Pharmacopeia 30 - National Formulary 25 ed.; US Pharmacopeia: 2007.
48. Taylor, L. S.; Zografi, G. Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm. Res. 1997, 14 (12), 1691-1698.
49. Azarmi, S.; Ghaffari, F.; Lobenberg, R.; Nokhodchi, A. Mechanistic evaluation of the effect of thermal-treating on Eudragit RS matrices. Farmaco 2005, 60 (11-12), 925-930.
50. Bhugra, C.; Shmeis, R.; Pikal, M. J. Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin. J. Pharm. Sci. 2008, 97 (10), 4446-4458.
51. Wu, C.; Bein, T. Conducting polyaniline filaments in a mesoporous channel host. Science 1994, 264 (5166), 1757-1759.
52. Otsuka, M.; Kato, F.; Matsuda, Y. Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. Analyst 2001, 126, 1578-1582.
53. Steele, G., Preformulation predictions from small amount of compound as an aid to candidate drug selection. In Pharmaceutical preformulation and formulation - A practical guide from candidate drug selection to commercial dosage form; Gibson, M., Ed.; CRC Press: New York, 2001; p 59.
54. Ogata, Y. H.; Tsuboi, T.; Sakka, T.; Naito, S. Oxidation of Porous Silicon in Dry and Wet Environments under Mild Temperature Conditions. J. Porous. Mater. 2000, 7 (1), 63-66.
55. Bellet, D.; Dolino, G. X-ray diffraction studies of porous silicon. Thin Solid Films 1996, 276 (1-2), 1-6.
56. Kurozumi, M.; Nambu, N.; Nagai, T. Inclusion Compounds of Non-Steroidal Antiinflammatory and Other Slightly Water Soluble Drugs with α-and β-Cyclodextrins in Powdered Form. Chem. Pharm. Bull. 1975, 23 (12), 3062-3068.
57. Merck&Co, Indocid(R): Consumer Medicine Information; Victorian Government, Australia: 1994; pp 1-3.
58. Anderson, S. H. C.; Elliott, H.; Wallis, D. J.; Canham, L. T.; Powell, J. J. Dissolution of different forms of partially porous silicon wafers under simulated physiological conditions. Phys. Status Solidi A 2003, 197 (2), 331-335.
59. Coffer, J. L.; Whitehead, M. A.; Nagesha, D. K.; Mukherjee, P.; Akkaraju, G.; Totolici, M.; Saffie, R. S.; Canham, L. T. Porous silicon-based scaffolds for tissue engineering and other biomedical applications. Phys. Status Solidi A 2005, 202 (8), 1451-1455.
60. F.D.A. Guidance for Industry: Extended release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997, p 27.
61. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11 (Suppl. 2), S73-S80.
62. Drewe, J.; Guitard, P. In vitro-in vivo correlation for modifiedrelease formulations. J. Pharm. Sci. 1993, 82 (2), 132-137.
63. Sreenivasa Rao, B.; Seshasayana, A.; Pardha Saradhi, S. V.; Ravi Kumar, N.; Narayan, C. P. S.; Ramana Murthy, K. V. Correlation of 'in vitro' release and 'in vivo' absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads. Int. J. Pharm. 2001, 230 (1-2), 1-9.
64. Wagner, J. G.; Nelson, E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci. 1964, 53 (11), 1392-1403.
65. Li, S., Mueller-Zsigmondy; M. Yin, H., The role of in vitro-in vivo correlation in product development and life cycle management. In Pharmaceutical Product Development: In vitro-In vivo Correlation; Chilukuri, D. M., Sunkara, G.;,Young, D., Eds.; Informa: New York, 2007; Vol. 165, p 71.
66. Brockmeier, D.; Voegele, D.; Von Hattingberg, H. M. In vitro-in vivo correlation, a time scaling problem? Basic techniques for testing equivalence. Arzneim. Forsch. 1983, 33 (4), 598-601.
67. Löbenberg, R.; Amidon, G. L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50 (1), 3-12.
68. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in-vivo performance of class I and II drugs. Pharm. Res. 1998, 15 (5), 698-705.
69. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J. B.; Reppas, C. Forecasting the in-vivo performance of four loow solubility drugs from their in-vitro dissolution data. Pharm. Res. 1999, 16 (12), 1876-1882.
70. Costa, P.; Lobo, S. M. J. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13 (2), 123-133.